Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics

GuruFocus.com00:32

Novo Nordisk's (NYSE:NVO) latest findings from the SOUL trial signal a major win for both investors and patients. The study showed that Rybelsus, the company's oral form of semaglutide, slashed the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477895844?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NwPSVPl_GXOB7pNeh_OHiQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/aa6e73c90c570f4f612a8395ddab3318","is_english":true,"pubTime":"2024-10-22 00:32","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2477895844","market":"us","top_or_hot":-1,"title":"Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics","media":"GuruFocus.com","content":"<div>\n<p>Novo Nordisk's (NYSE:NVO) latest findings from the SOUL trial signal a major win for both investors and patients. The study showed that Rybelsus, the company's oral form of semaglutide, slashed the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novo-nordisks-rybelsus-sets-standard-163208555.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-22 00:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novo-nordisks-rybelsus-sets-standard-163208555.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk's (NYSE:NVO) latest findings from the SOUL trial signal a major win for both investors and patients. The study showed that Rybelsus, the company's oral form of semaglutide, slashed the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novo-nordisks-rybelsus-sets-standard-163208555.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://finance.yahoo.com/news/novo-nordisks-rybelsus-sets-standard-163208555.html","article_id":"2477895844","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NwPSVPl_GXOB7pNeh_OHiQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/aa6e73c90c570f4f612a8395ddab3318"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477895844","pubTimestamp":1729528328,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Novo Nordisk's  latest findings from the SOUL trial signal a major win for both investors and patients. The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney complications. With 9,650 participants, the data couldn't be clearerRybelsus didn't just manage diabetes; it lowered the odds of life-threatening events like heart attacks and strokes. This positions Novo Nordisk to redefine standard care, expanding beyond diabetes management and setting the stage for broader market dominance.GuruFocus has detected 1 Warning Sign with NVO.Now, Novo Nordisk is gearing up to file for regulatory approval in the U.S. and E.U. by early next year. With Rybelsus showing promise beyond diabetes, Novo is poised to make waves in other areasAlzheimer's, alcohol-related disorders, you name it. This isn't just a drug; it's a versatile growth engine, opening up fresh avenue","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","NVO":"诺和诺德","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","CSII":"Cardiovascular Systems","BK4532":"文艺复兴科技持仓","BK4124":"机动车零配件与设备","SMP":"Standard Motor Products Inc","BK4082":"医疗保健设备","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"诺和诺德Rybelsus树立新标准：糖尿病患者心血管风险降低14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSII":1,"NVO":1,"SMP":1},"content_text":"Novo Nordisk's (NYSE:NVO) latest findings from the SOUL trial signal a major win for both investors and patients. The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney complications. With 9,650 participants, the data couldn't be clearerRybelsus didn't just manage diabetes; it lowered the odds of life-threatening events like heart attacks and strokes. This positions Novo Nordisk to redefine standard care, expanding beyond diabetes management and setting the stage for broader market dominance.\n\nWarning! GuruFocus has detected 1 Warning Sign with NVO.\n\nThe stakes are highroughly one-third of adults with type 2 diabetes also contend with cardiovascular disease, creating an urgent demand for treatments that tackle both. Novo's executive vice president, Martin Holst Lange, didn't mince words when he said the drug's safety profile aligns with past results, confirming Rybelsus as a game-changer. It's not just about adding another medication to the regimen; it's about potentially saving lives and setting a new benchmark in patient care.\nNow, Novo Nordisk is gearing up to file for regulatory approval in the U.S. and E.U. by early next year. With Rybelsus showing promise beyond diabetes, Novo is poised to make waves in other areasAlzheimer's, alcohol-related disorders, you name it. This isn't just a drug; it's a versatile growth engine, opening up fresh avenues for expansion and positioning Novo Nordisk to capture a larger slice of the healthcare market.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477895844"}